Cell No. : Cell Name
RCB1188 : NRS-1
update : 2022/03/30
|
| Comment | Human rhabdomyosarcoma showing myogenic differentiation. TGFbeta inhibits it. Application consideration |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Motoyama, Teiichi
|
| Originator |
Ogose, Akira & Motoyama, Teiichi
|
| Year of deposit |
1995
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Female
|
| Age at sampling |
7 years
|
| Tissue |
left forearm
|
| Disease name |
alveolar rhabdomyosarcoma
|
| Metastatic ability |
Yes
|
| Metastatic tissue |
left peroneus
|
| Classification |
cancer
|
| Year of origin |
1992
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_4871
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
MEM ALPHA + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/10 days, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
84-180(50) : /89(6),90(6),91(2),92(6),93(6),94(7)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
4
|
| User's Publication |
|
13263
Kato K, Yoshimi A, Noda A, Otani H, Hojo H, Tanaka M, Tanaka Y, Ito Y, Nishimura R, Takita J, Yanai T, Koike K, Tsuchida M.
Distinct clonal evolution in a case with anaplastic embryonal rhabdomyosarcoma.
Pediatr Int
2021
63(7):782-789
PubMed ID: 33021000
DOI: 10.1111/ped.14499
|
|
9801
Jaaks P, D'Alessandro V, Grob N, Büel S, Hajdin K, Schäfer BW, Bernasconi M.
The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.
PLoS ONE
2016
11:e0161396
PubMed ID: 27548722
DOI: 10.1371/journal.pone.0161396
|
|
6474
Yoshitaka T, Kawai A, Miyaki S, Numoto K, Kikuta K, Ozaki T, Lotz M, Asahara H.
Analysis of microRNAs expressions in chondrosarcoma.
J Orthop Res
2013
31(12):1992-8.
PubMed ID: 23940002
DOI: 10.1002/jor.22457
|
|
6475
Osaki M, Osaki M, Yamashita H, Shomori K, Yoshida H, Ito H.
Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: Correlations with Ki-67 and P53 expression, and apoptosis.
Int J Mol Med
2002
10(2):161-8
PubMed ID: 12119552
|
Back
Top
CELL BANK Website
